Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biogen's New EVP Commercial Ops Tony Kingsley: An Interview With "The Pink Sheet" DAILY

This article was originally published in The Pink Sheet Daily

Executive Summary

Execution, discipline, and reliance on proven sales and marketing methods helped turn around key multiple sclerosis drug Avonex, says Biogen's new EVP, Global Commercial Operations.

You may also be interested in...

Energized Biogen Idec On Track For Two Filings In 2012

Biogen hopes to submit marketing applications in the U.S. and Europe for both MS therapy BG-12 and its therapies for hemophilia A and B in 2012, with launches possible in early and mid-2013.

Biogen Ends Its Corporate Venture Efforts

Biogen CEO George Scangos spoke about the unnecessary overlap of the company's corporate venture fund and its business development unit at Windhover's recent Pharmaceutical Strategic Alliance conference.

Pharma In The Brave New World Of Corporatized Care

Still transforming their organizations to deal with the waning influence of the individual prescriber, pharma commercial leaders now face a new challenge: the growth of the corporate model of care, as large numbers of US physicians exchange the independence of physician-ownership for the predictability of working as employees in larger organizations. Corporate models of care, characterized by more centralized decision making, add a new dimension of customer complexity in an already tough environment.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts